Radiopharm Theranostics Limited (ASX: RAD) - Share Price

- Current share price for RAD : $0.019

Radiopharm Theranostics Limited (RAD), an ASX-listed company, operates as a clinical stage radiotherapeutics organisation developing a platform of radiopharmaceutical products for diagnostic and therapeutic use in areas of unmet medical need. The development pipeline consists of platform technologies that include peptides, small molecules, and monoclonal antibodies for cancer applications.

RAD General Information ⁺

ASX Code	RAD
Website	N/A
Industry/Sector	Biotechnology
Market Cap ($M)	67
RAD Share Price	$0.019
Day High	$0.020
Day Low	$0.019
Last Close	$0.019
RAD Share Price Movement	- ( No change )

Prices as at 16:36, 22 Jul 2026

⁺Security prices are delayed by at least 20 minutes and are indicative only.

Radiopharm Theranostics Limited (RAD) Upcoming Dividends & Yields

Distribution Type	Dividend	Franking	Ex-dividend date	Payment date	Current Price⁺	Price 7D Avg	Dividend Yield

See all dividends from Radiopharm Theranostics Limited (RAD) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Radiopharm Theranostics Limited (RAD) price-sensitive announcements

RAD - Quarterly Activities/Appendix 4C Cash Flow Report

Radiopharm Theranostics Limited, a clinical-stage biopharmaceutical company, reported its

Radiopharm Theranostics Limited (RAD)
23 Apr 2026 | 9:04 AM

RAD - RAD Completes Enrollment in Phase 2b Trial of RAD 101

Radiopharm Theranostics Limited announced the completion of enrolment for its U.S. Phase 2

Radiopharm Theranostics Limited (RAD)
16 Apr 2026 | 8:41 AM

RAD - RAD202 Phase 1 HEAT Trial Advances to Dose Level 3

Radiopharm Theranostics has advanced to the third cohort in its Phase 1 'HEAT' clinical tr

Radiopharm Theranostics Limited (RAD)
8 Apr 2026 | 9:00 AM

RAD - RAD Doses First Patient in RAD 402 Phase 1 Clinical Study

Radiopharm Theranostics Limited, a clinical-stage biopharmaceutical company, announced the

Radiopharm Theranostics Limited (RAD)
27 Mar 2026 | 8:23 AM

Radiopharm Theranostics Limited (RAD) Recent ASX Announcements

Company	Sector	Market Cap ($m)	Headline	Release date/time⁺	Price at release⁺	Current price⁺	Gain/Loss
Radiopharm Theranostics Limited (RAD) ORDINARY FULLY PAID	Health Care	$67	Trading Halt	22 Jul 2026 9:04AM	$0.019	$0.019	fallen by 0%
Radiopharm Theranostics Limited (RAD) ORDINARY FULLY PAID	Health Care	$67	RAD Achieves Partial Response in Phase 1 Trial of RAD204	22 Jul 2026 8:32AM	$0.019	$0.019	fallen by 0%
Radiopharm Theranostics Limited (RAD) ORDINARY FULLY PAID	Health Care	$67	RAD Announces Positive Phase 2b Trial Results of RAD 101	22 Jul 2026 8:22AM	$0.019	$0.019	fallen by 0%
Radiopharm Theranostics Limited (RAD) ORDINARY FULLY PAID	Health Care	$67	Radiopharm Receives $5.9M R&D Tax Incentive	3 Jul 2026 3:20PM	$0.019	$0.019	fallen by 0%
Radiopharm Theranostics Limited (RAD) ORDINARY FULLY PAID	Health Care	$67	Notification regarding unquoted securities - RAD	30 Jun 2026 4:15PM	$0.019	$0.019	fallen by 0%
Radiopharm Theranostics Limited (RAD) ORDINARY FULLY PAID	Health Care	$67	Notification of cessation of securities - RAD	30 Jun 2026 4:05PM	$0.020	$0.019	fallen by 2.56%

RAD Financial Summary

Year to Jun	NPAT	EPS	EPS chg (%)	Yield (%)	Franking (%)
2027F	C2	-$1.00	46.40%	0.00%	0.0%
2026F	C2	-$0.70	-56.10%	0.00%	0.0%
2025A	-$34.27	-$1.60	-83.90%	0.00%	0.0%

RAD Peer Comparison

Company	Mkt Cap	EPS Growth (%)			P/E (%)			Dividend Yield (%)
Company	Mkt Cap	2025 A	2026 F	2027 F	2025 A	2026 F	2027 F	2025 A	2026 F	2027 F
CSL Limited (CSL)	$58,719M	0.1108	-0.1183	0.0168	13.1475	14.9110	14.6650	3.64%	2.98%	3.10%
Clinuvel Pharmaceuticals Limited (CUV)	$516M	0.0287	0.0000	0.0000	14.2618	0.0000	0.0000	0.49%	0.00%	0.00%
Mesoblast Limited (MSB)	$3,151M	0.0301	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
Radiopharm Theranostics Limited (RAD)	$71M	-0.8386	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
Telix Pharmaceuticals Limited (TLX)	$5,131M	-1.3893	0.0000	-0.1298	0.0000	276.0512	317.2269	0.00%	0.00%	0.00%

RAD Directors

Name	Position	Start Date
Mr Riccardo Canevari	Chief Executive Officer, Managing Director	13 Sep 2021
Mr Paul Alex Hopper	Executive Chairman, Founder, Executive Director	11 Feb 2021
Mr Ian Turner	Non-Executive Director	1 Apr 2021
Ms Hester Larkin	Non-Executive Director	3 Feb 2022
Mr Noel Donnelly	Non-Executive Director	1 Oct 2024
Mr Bruce Goodwin	Non-Executive Director	19 Nov 2025

Radiopharm Theranostics Limited (RAD) Changes in Directors' Interest & Trades

Date of change	Director	Buy/Sell	Security Type	Qty	Trade Price	Value
25 Mar 2026	TURNER, Ian	Buy	Indirect Shares	730,000	$0.019	$13,870.000
30 Oct 2025	CANEVARI, Riccardo	Buy	Indirect Shares	1,500,000	$0.025	$37,500.000
23 May 2025	TURNER, Ian	Buy	Indirect Shares	3,000,000	$0.029	$87,000.000

See all changes in directors' interest & trades for Radiopharm Theranostics Limited (RAD) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

RAD Management

Name	Position
Dimitris Voliotis	Chief Medical Officer
Amritha Sushil	Joint Company Secretary
Nathan Kim -liung Jong	Joint Company Secretary

RAD Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Radiopharm Theranostics Limited (RAD). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding	Name
282,958,513 (12.12%)	Lantheus Omega, LLC
145,362,288 (7.30%)	Regal Funds Management Pty Ltd
149,221,428 (6.90%)	Paul Hopper
174,583,414 (6.90%)	JPmorgan Chase & Co. and its affiliates

RAD Calendar of Events

Date	Event
26 February 2027	Report (Interim)
16 September 2026	Report (Annual)
28 August 2026	Report (Prelim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.

What our members say about us